No Data
Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-6768 injection has received the clinical trial approval notification.
On January 3rd, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary Tianjin Hengrui Pharmaceuticals Co., Ltd. received the approval notice for the clinical trial of HRS-6768 injection issued by the National Medical Products Administration. Clinical trials will be conducted in the near future. HRS-6768 injection is a Class 1 Innovative Drug for radioactive therapy independently developed by the company, and no similar products have been approved for marketing either domestically or internationally. This product is suitable for patients with advanced solid tumors who are positive for fibroblast activation protein.
Jiangsu Hengrui Pharmaceuticals (600276.SH): A total of 5.18 million shares have been repurchased.
Gelonghui, January 2nd丨Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that as of December 31, 2024, the company has repurchased a total of 5,181,144 shares through centralized bidding, accounting for 0.08% of the company's total share capital. The highest transaction price was 57.54 yuan/share, and the lowest was 39.00 yuan/share, with a total amount paid of 218,405,956.60 yuan (excluding transaction fees).
IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849
Open Source Securities: DLL3 is a star target with high expression in SCLC, and various domestic new drugs can be expected in the future.
DLL3 is highly expressed in 80% of SCLC patients, providing a better solution for targeted therapy. Currently, only one product targeting this point has been approved for market, resulting in a favorable competitive landscape.
Should Weakness in Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Jiangsu Hengrui Pharmaceuticals (600276.SH): Signed a licensing agreement for the SHR-4849 project with IDEAYA Biosciences.
On December 29, Gu Longhui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced an agreement with IDEAYA Biosciences, whereby the company granted IDEAYA Biosciences a paid license for the injectable new drug SHR-4849, which has independent intellectual property rights. SHR-4849 is an antibody-drug conjugate (ADC) targeting DLL3 developed by Hengrui with its own intellectual property.
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
No Data
